| Oct 6 |
Billionaires Are Loading Up on This High-Yield Dividend Stock. Should You?
|
| Oct 5 |
2 Top Dividend Stocks Yielding 3% or More to Buy Without Hesitation Right Now
|
| Oct 4 |
Pharma Stock Roundup: FDA Approves SNY's Dupixent for COPD & More
|
| Oct 4 |
AbbVie Cuts 2024 Earnings Guidance to Include Acquisition Costs
|
| Oct 4 |
Allergan Aesthetics and Girls Inc. Celebrate Six Years and Challenge You to Take the Pledge to Support Mentorship in STEM
|
| Oct 4 |
AbbVie’s atogepant set to reach projected worth of $766m in 2026 after accepted NDA from FDA
|
| Oct 3 |
AbbVie lowers 2024 earnings forecast by $0.04 per share
|
| Oct 3 |
AbbVie cuts 2024 profit forecast on R&D expenses
|
| Oct 3 |
Blue Shield of California Slashes Humira Biosimilar Prices in Landmark Deal
|
| Oct 3 |
AbbVie's Emraclidine: M4 Agonist Might Become Best-In-Class In Schizophrenia
|
